Skip to main content

Advertisement

Table 3 Representative incremental cost-effectiveness ratio for each drug indication in increasing order

From: International comparison of the factors influencing reimbursement of targeted anti-cancer drugs

Drug Indications ICER ( in US$) *
Nilotinib Chronic myeloid leukemia, chronic phase: 1st-line 17,314
Imatinib Gastrointestinal stromal tumor: Adjuvant therapy 29,591
Cetuximab Colorectal cancer (K-RAS wild type): 1st line with oxaliplatin, fluorouracil, and folinic acid 42,026
Pemetrexed NSCLC (for non-squamous histology): 1st line with cisplatin 44,451
Lenalidomide Multiple myeloma: 1st-line 68,941
Pemetrexed NSCLC: Maintenance treatment 73,978
Sorafenib Liver cancer: 1st line 82,792
Sunitinib Renal cell carcinoma: 1st line 85,572
Lapatinib Breast cancer with HER2 overexpression: 2nd line with capecitabine 93,496
Bevacizumab Colorectal cancer: with irinotecan, fluorouracil, and leucovorin 98,937
Bevacizumab Colorectal cancer: with oxaliplatin, fluorouracil, and folinic acid 110,967
Dasatinib Chronic myeloid leukemia, chronic phase: 1st-line 118,050
Cetuximab Colorectal cancer: with irinotecan 121,528
Temsirolimus Renal cell carcinoma: 1st-line for poor prognosis patients 128,595
Bevacizumab Renal cell carcinoma: 1st line with interferon-α 131,070
Crizotinib NSCLC (ALK fusion positive): 2nd line (vs. docetaxel) 158,133
Bevacizumab NSCLC: 1st line with platinum-based chemotherapy 196,000
Cetuximab Head and neck cancer (squamous cell carcinoma) : 1st line with platinum-based chemotherapy 261,767
Erlotinib Pancreatic cancer: 1st line with gemcitabine 430,000
  1. ICER, Incremental Cost Effectiveness Ratio; NSCLC, non-small cell lung cancer.
  2. *Most ICER values except two indications were retrieved from the National Institute for Health and Clinical Excellence in United Kingdom (costs are expressed in US dollars; £1 equals $1.574 (as of January 29, 2013)).
  3. This value was from the Pharmaceutical Benefits Advisory Committee in Australia. (Canadian $1 equals US $0.98) http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2011-03/pbac-psd-bevacizumab-march11.
  4. This value was from Miksad RA et al. J Clin Oncol 25:4506–7; author reply 4508, 2007.